戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 eline in daytime symptom score was -0.62 for beclomethasone, -0.41 for montelukast, and -0.17 for pla
2  used the clinically relevant corticosteroid beclomethasone-17-monopropionate (17-BMP) to assess GR f
3 lukast, 10 mg once daily at bedtime; inhaled beclomethasone, 200 microg twice daily, administered wit
4 ily beclomethasone treatment was one puff of beclomethasone (40 mug per puff) or placebo given in the
5  change from baseline in FEV1 was 13.1% with beclomethasone, 7.4% with montelukast, and 0.7% with pla
6 d costs of extrafine hydrofluoroalkane (HFA)-beclomethasone and fluticasone administered through a pr
7 almeterol was inferior to the combination of beclomethasone and salmeterol as judged by protection ag
8 d salmeterol to that with the combination of beclomethasone and salmeterol in moderate asthma.
9 1; 79.9% budesonide, 17.6% fluticasone, 5.4% beclomethasone, and 0.9% other or unspecified glucocorti
10    One hundred twenty-three infants received beclomethasone, and 130 received placebo.
11 uptake of 10 pharmaceuticals (acetazolamide, beclomethasone, carbamazepine, diclofenac, gemfibrozil,
12 nisolide-CFC - 936; triamcinolone-CFC - 787; beclomethasone-CFC - 548; fluticasone DPI - 445; budeson
13       For the six ICS and matching placebos (beclomethasone-chlorofluorocarbon [CFC], budesonide dry
14 ith placebo for each end point; P < 0.01 for beclomethasone compared with montelukast for each end po
15 reatment compared with placebo; P < 0.01 for beclomethasone compared with montelukast).
16 reatment compared with placebo; P < 0.01 for beclomethasone compared with montelukast).
17 placebo (in a 2:1 ratio) in combination with beclomethasone dipropionate (6 to 16 inhalations per day
18 e exposed to 0.1 mug/L, 1 mug/L, or 10 mug/L beclomethasone dipropionate (BCMD) via a flow-through sy
19 ts of two widely prescribed glucocorticoids, beclomethasone dipropionate (BDP) and prednisolone aceta
20  ability of dexamethasone (DEX) in vitro and beclomethasone dipropionate (BDP) in vivo to induce beta
21  fish model and the synthetic glucocorticoid beclomethasone dipropionate (BDP) to investigate the rol
22           We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastroin
23 ment period and a 6-wk treatment period with beclomethasone dipropionate (BDP), 336 microg/d.
24                                              Beclomethasone dipropionate (BDP), a topically active st
25 ulations of the inhaled corticosteroid (ICS) beclomethasone dipropionate (BDP), long-acting B(2)-agon
26 cle aerosols such as HFA-ciclesonide and HFA-beclomethasone dipropionate (HFA-BDP) enables a higher d
27 ose of extra-fine particle hydrofluoroalkane beclomethasone dipropionate (mean dose 355ug).
28 hows clinical efficacy equivalent to that of beclomethasone dipropionate 400 mug daily.
29 V1 ; FEV1 <65% vs >/=65% predicted], inhaled beclomethasone dipropionate dose [<600 vs >/=600 mug/day
30 nts were 100 and 800 micron/d of an HFA-134a beclomethasone dipropionate formulation.
31 on 60 minutes after inhalation of 800 microg beclomethasone dipropionate in six healthy subjects.
32 re bundles with the synthetic glucocorticoid beclomethasone dipropionate increased the phosphorylatio
33  seventy-four patients with asthma receiving beclomethasone dipropionate or triamcinolone acetonide d
34 twice per day, equivalent to 800 mug per day beclomethasone dipropionate) or placebo.
35  effectiveness of an inhaled corticosteroid (beclomethasone dipropionate) used as rescue treatment.
36 r-triggered inhaled glucocorticoid strategy (beclomethasone dipropionate, 80 mug) plus usual care (in
37                                              Beclomethasone dipropionate, 84 microg twice a day, was
38     Participants received 6 weeks of inhaled beclomethasone dipropionate.
39 ents before and after treatment with inhaled beclomethasone, DNO averaged 6.8 +/- 1.2, 25.5 +/- 3.8,
40                               Prescribed HFA-beclomethasone doses were lower (P < .001) than fluticas
41                     After a 4-week run-in on beclomethasone/formoterol maintenance and reliever thera
42                                              Beclomethasone/formoterol maintenance and reliever thera
43 oup at 28 days of age, and 18 percent in the beclomethasone group and 20 percent in the placebo group
44 similar in the two groups: 43 percent in the beclomethasone group and 45 percent in the placebo group
45  had severe adverse events; one in the daily beclomethasone group had viral meningitis and one in the
46      At 28 days of age, fewer infants in the beclomethasone group than in the placebo group were rece
47 lomethasone plus albuterol as rescue (rescue beclomethasone group); and twice daily placebo with plac
48 with placebo plus albuterol as rescue (daily beclomethasone group); twice daily placebo with beclomet
49                                     Although beclomethasone had a greater mean clinical benefit than
50                                     Although beclomethasone had a larger mean effect than montelukast
51                      Patients started on HFA-beclomethasone had significantly higher odds (adjusted o
52  (n=71), daily beclomethasone (n=72), rescue beclomethasone (n=71), and placebo (n=74)-555 individual
53 our treatment groups; combined (n=71), daily beclomethasone (n=72), rescue beclomethasone (n=71), and
54 to 80 years receiving their first ICS as HFA-beclomethasone or fluticasone and matched on baseline de
55 ue beclomethasone treatment was two puffs of beclomethasone or placebo for each two puffs of albutero
56 d a randomized, multicenter trial of inhaled beclomethasone or placebo in 253 infants, 3 to 14 days o
57  approaches including topical agents such as beclomethasone or sirolimus as a steroid-free approach t
58 ment groups: twice daily beclomethasone with beclomethasone plus albuterol as rescue (combined group)
59 lomethasone group); twice daily placebo with beclomethasone plus albuterol as rescue (rescue beclomet
60 ent outcomes were similar or better with HFA-beclomethasone prescribed at significantly lower doses a
61 5% CI, $165-$620) per patient prescribed HFA-beclomethasone rather than fluticasone.
62  care costs were significantly lower for HFA-beclomethasone than fluticasone (mean, $1869 [95% CI, $1
63                                        Early beclomethasone therapy did not prevent bronchopulmonary
64                                  Twice daily beclomethasone treatment was one puff of beclomethasone
65                                       Rescue beclomethasone treatment was two puffs of beclomethasone
66                                              Beclomethasone was delivered in a decreasing dosage, fro
67 to one of four treatment groups: twice daily beclomethasone with beclomethasone plus albuterol as res
68 erol as rescue (combined group); twice daily beclomethasone with placebo plus albuterol as rescue (da